Compare EMO & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMO | CYRX |
|---|---|---|
| Founded | 2011 | 1999 |
| Country | United States | United States |
| Employees | N/A | 1100 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 883.3M |
| IPO Year | N/A | 2008 |
| Metric | EMO | CYRX |
|---|---|---|
| Price | $50.56 | $16.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $19.78 |
| AVG Volume (30 Days) | 31.6K | ★ 766.5K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 6.70% | N/A |
| EPS Growth | N/A | ★ 156.22 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $176,177,000.00 |
| Revenue This Year | N/A | $10.95 |
| Revenue Next Year | N/A | $10.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $41.54 | $7.61 |
| 52 Week High | $56.33 | $18.88 |
| Indicator | EMO | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 42.36 |
| Support Level | $49.73 | $14.55 |
| Resistance Level | $53.33 | $16.87 |
| Average True Range (ATR) | 1.09 | 0.82 |
| MACD | 0.29 | -0.17 |
| Stochastic Oscillator | 49.81 | 12.90 |
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.